107 related articles for article (PubMed ID: 25647738)
1. Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer.
Toge M; Yokoyama S; Kato S; Sakurai H; Senda K; Doki Y; Hayakawa Y; Yoshimura N; Saiki I
Int J Oncol; 2015 Apr; 46(4):1844-8. PubMed ID: 25647738
[TBL] [Abstract][Full Text] [Related]
2. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
Ma J; Zhao Z; Wu K; Xu Z; Liu K
Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804
[TBL] [Abstract][Full Text] [Related]
3. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.
Whitsett TG; Mathews IT; Cardone MH; Lena RJ; Pierceall WE; Bittner M; Sima C; LoBello J; Weiss GJ; Tran NL
Mol Cancer Res; 2014 Apr; 12(4):550-9. PubMed ID: 24469836
[TBL] [Abstract][Full Text] [Related]
5. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
6. Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.
Wang J; Chen Y; Xiang F; Li M; Li H; Chi J; Ren K
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1505-1512. PubMed ID: 28918673
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
9. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N
Cancer Biol Med; 2020 May; 17(2):387-400. PubMed ID: 32587776
[No Abstract] [Full Text] [Related]
10. Caspase cleavage of Mcl-1 impairs its anti-apoptotic activity and proteasomal degradation in non-small lung cancer cells.
Wang T; Yang Z; Zhang Y; Zhang X; Wang L; Zhang S; Jia L
Apoptosis; 2018 Jan; 23(1):54-64. PubMed ID: 29256070
[TBL] [Abstract][Full Text] [Related]
11. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration.
Lee MW; Kim DS; Lee JH; Lee BS; Lee SH; Jung HL; Sung KW; Kim HT; Yoo KH; Koo HH
Cancer Sci; 2011 Oct; 102(10):1822-8. PubMed ID: 21722267
[TBL] [Abstract][Full Text] [Related]
12. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6.
Abulaiti A; Shintani Y; Funaki S; Nakagiri T; Inoue M; Sawabata N; Minami M; Okumura M
Lung Cancer; 2013 Nov; 82(2):204-13. PubMed ID: 24011634
[TBL] [Abstract][Full Text] [Related]
13. EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells.
Liu LC; Tsao TC; Hsu SR; Wang HC; Tsai TC; Kao JY; Way TD
J Agric Food Chem; 2012 Oct; 60(39):9863-73. PubMed ID: 22957988
[TBL] [Abstract][Full Text] [Related]
14. Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.
Yan J; Zhong N; Liu G; Chen K; Liu X; Su L; Singhal S
Cell Death Dis; 2014 Jul; 5(7):e1316. PubMed ID: 24991768
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
[TBL] [Abstract][Full Text] [Related]
16. TGF-β-activated SMAD3/4 complex transcriptionally upregulates N-cadherin expression in non-small cell lung cancer.
Yang H; Wang L; Zhao J; Chen Y; Lei Z; Liu X; Xia W; Guo L; Zhang HT
Lung Cancer; 2015 Mar; 87(3):249-57. PubMed ID: 25595426
[TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
18. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Li J; Viallet J; Haura EB
Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
[TBL] [Abstract][Full Text] [Related]
19. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
